IRVINE, Calif., Aug. 16, 2006 (PRIMEZONE) -- "Even companies which utilize non-controversial sources for stem cells are finding that international alliances are beneficial to their business plans," stated SmallCap Sentinel analyst D.R. Clark.
"For example, Medistem Laboratories, Inc. (OTCBB:MDSM), which is committed to the ethical development of next-generation medical therapies from non-controversial adult stem cell sources, has announced that its affiliate, the Institute for Cellular Medicine (ICM), has received approval from the Costa Rican Health Ministry to begin operations of its adult stem cell bank and clinic," Clark added.
"With the opening of the ICM stem cell bank and clinic, Medistem takes a critical leap forward in executing its core business plan of developing and licensing potentially pioneering stem cell treatments worldwide on a fee-for-service basis," said Clark.
Medistem Laboratories is an innovative biotechnology company committed to the creation, licensing and commercialization of advanced medical therapies based on non-controversial adult stem cells. The company intends to use adult stem cells generated from muscle, bone marrow and fat of adult patients seeking treatment, as well as from full-term, healthy placentas and umbilical cords, which the company believes to be non-controversial sources of stem cells. The company's business strategy calls for the establishment of a series of adult stem cell banks and clinics around the world to deliver unprecedented, next-generation cell therapies to help millions of patients.
For more information on Medistem please visit: http://www.trilogy-capital.com/tcp/medistem/.
Individuals may also register to receive future informational reports at: http://stockupticks.com/register.html
The informational report "Looking at the Political Impact on Stem Cell Research" is available at www.SmallCapSentinel.com and will address stem cell companies including StemCells Inc. (Nasdaq:STEM), Aastrom Biosciences Inc. (Nasdaq:ASTM), Geron Corp. (Nasdaq:GERN) and Medistem Laboratories (OTCBB:MDSM).
Statements made herein contain forward-looking statements and are subject to significant risks and uncertainties that affect results. SmallCap Sentinel and StockUpTicks.com are properties of Market Pathways Financial Relations Inc. (MP). MP provides no assurance as to the subject company's plans or ability to effect any proposed actions and cannot project capabilities, intent, resources, or experience.
Information contained herein is based upon sources believed to be reliable but no representation is made as to accuracy or completeness. This report is neither a solicitation to buy, nor offer to sell securities, but is rather a paid advertisement provided for information purposes only and shouldn't be used as basis for any investment decision. MP is not an investment advisor and this report is not investment advice. MP has been paid $1,500 by Medistem for preparation and distribution of this report and other advertising services. An editor of SmallCap Sentinel currently holds a position in STEM. This constitutes a conflict of interest as to MP's ability to remain objective in communication regarding the subject companies.